Texas 2021 - 87th Regular

Texas House Bill HB2593 Latest Draft

Bill / Comm Sub Version Filed 05/20/2021

                            By: Moody, et al. H.B. No. 2593
 (Senate Sponsor - Johnson, Hinojosa)
 (In the Senate - Received from the House April 28, 2021;
 May 14, 2021, read first time and referred to Committee on State
 Affairs; May 20, 2021, reported favorably by the following vote:
 Yeas 7, Nays 2; May 20, 2021, sent to printer.)
Click here to see the committee vote


 A BILL TO BE ENTITLED
 AN ACT
 relating to the criminal penalties for the possession of certain
 tetrahydrocannabinols under the Texas Controlled Substances Act.
 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
 SECTION 1.  Sections 481.002(5) and (6), Health and Safety
 Code, are amended to read as follows:
 (5)  "Controlled substance" means a substance,
 including a drug, an adulterant, and a dilutant, listed in
 Schedules I through V or Penalty Group 1, 1-A, 2, 2-A, 2-B, 3, or 4.
 The term includes the aggregate weight of any mixture, solution, or
 other substance containing a controlled substance. The term does
 not include hemp, as defined by Section 121.001, Agriculture Code,
 or the tetrahydrocannabinols in hemp.
 (6)  "Controlled substance analogue" means:
 (A)  a substance with a chemical structure
 substantially similar to the chemical structure of a controlled
 substance in Schedule I or II or Penalty Group 1, 1-A, 2, [or] 2-A,
 or 2-B; or
 (B)  a substance specifically designed to produce
 an effect substantially similar to, or greater than, the effect of a
 controlled substance in Schedule I or II or Penalty Group 1, 1-A, 2,
 [or] 2-A, or 2-B.
 SECTION 2.  Section 481.103(a), Health and Safety Code, is
 amended to read as follows:
 (a)  Penalty Group 2 consists of:
 (1)  any quantity of the following hallucinogenic
 substances, their salts, isomers, and salts of isomers, unless
 specifically excepted, if the existence of these salts, isomers,
 and salts of isomers is possible within the specific chemical
 designation:
 5-(2-aminopropyl)benzofuran (5-APB);
 6-(2-aminopropyl)benzofuran (6-APB);
 5-(2-aminopropyl)-2,3-dihydrobenzofuran
 (5-APDB);
 6-(2-aminopropyl)-2,3-dihydrobenzofuran
 (6-APDB);
 5-(2-aminopropyl)indole (5-IT,5-API);
 6-(2-aminopropyl)indole (6-IT,6-API);
 1-(benzofuran-5-yl)-N-methylpropan-2-amine
 (5-MAPB);
 1-(benzofuran-6-yl)-N-methylpropan-2-amine
 (6-MAPB);
 Benzothiophenylcyclohexylpiperidine (BTCP);
 8-bromo-alpha-methyl-benzo[1,2-b:4,5-b']difuran-
 4-ethanamine (trade or other name: Bromo-DragonFLY);
 Desoxypipradrol (2-benzhydrylpiperidine);
 2, 5-dimethoxyamphetamine (some trade or other
 names:  2, 5-dimethoxy-alpha-methylphenethylamine; 2, 5-DMA);
 Diphenylprolinol (diphenyl(pyrrolidin-2-yl)
 methanol, D2PM);
 Dronabinol (synthetic) in sesame oil and
 encapsulated in a soft gelatin capsule in a U.S. Food and Drug
 Administration approved drug product (some trade or other names for
 Dronabinol:  (a6aR-trans)-6a,7,8,10a-tetrahydro- 6,6, 9-
 trimethyl-3-pentyl-6H- dibenzo [b,d]pyran-1-ol or (-)-delta-9-
 (trans)- tetrahydrocannabinol);
 Ethylamine Analog of Phencyclidine (some trade or
 other names:  N-ethyl-1-phenylcyclohexylamine, (1-
 phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine,
 cyclohexamine, PCE);
 2-ethylamino-2-(3-methoxyphenyl)cyclohexanone
 (trade or other name: methoxetamine);
 Ibogaine (some trade or other names:  7-Ethyl-6,
 6, beta 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H-
 pyrido [1', 2':1, 2] azepino [5, 4-b] indole; tabernanthe iboga.);
 5-iodo-2-aminoindane (5-IAI);
 Mescaline;
 5-methoxy-3, 4-methylenedioxy amphetamine;
 4-methoxyamphetamine (some trade or other
 names:  4-methoxy-alpha-methylphenethylamine;
 paramethoxyamphetamine; PMA);
 4-methoxymethamphetamine (PMMA);
 2-(2-methoxyphenyl)-2-(methylamino)cyclohexanone
 (some trade and other names: 2-MeO-ketamine; methoxyketamine);
 1-methyl- 4-phenyl-4-propionoxypiperidine (MPPP,
 PPMP);
 4-methyl-2, 5-dimethoxyamphetamine (some trade
 and other names:  4-methyl-2, 5-dimethoxy-alpha-
 methylphenethylamine; "DOM"; "STP");
 3,4-methylenedioxy methamphetamine (MDMA, MDM);
 3,4-methylenedioxy amphetamine;
 3,4-methylenedioxy N-ethylamphetamine (Also
 known as N-ethyl MDA);
 5,6-methylenedioxy-2-aminoindane (MDAI);
 Nabilone (Another name for nabilone:  (+)-trans-
 3-(1,1-dimethylheptyl)- 6,6a, 7,8,10,10a-hexahydro-1-hydroxy- 6,
 6-dimethyl-9H-dibenzo[b,d] pyran-9-one;
 N-benzylpiperazine (some trade or other
 names:  BZP; 1-benzylpiperazine);
 N-ethyl-3-piperidyl benzilate;
 N-hydroxy-3,4-methylenedioxyamphetamine (Also
 known as N-hydroxy MDA);
 4-methylaminorex;
 N-methyl-3-piperidyl benzilate;
 Parahexyl (some trade or other names:  3-Hexyl-1-
 hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b, d]
 pyran; Synhexyl);
 1-Phenylcyclohexylamine;
 1-Piperidinocyclohexanecarbonitrile (PCC);
 Pyrrolidine Analog of Phencyclidine (some trade
 or other names:  1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP);
 [Tetrahydrocannabinols, other than marihuana, and
 synthetic equivalents of the substances contained in the plant, or
 in the resinous extractives of Cannabis, or synthetic substances,
 derivatives, and their isomers with similar chemical structure and
 pharmacological activity such as:
 [delta-1 cis or trans tetrahydrocannabinol,
 and their optical isomers;
 [delta-6 cis or trans tetrahydrocannabinol,
 and their optical isomers;
 [delta-3, 4 cis or trans
 tetrahydrocannabinol, and its optical isomers; or
 [compounds of these structures, regardless
 of numerical designation of atomic positions, since nomenclature of
 these substances is not internationally standardized;]
 Thiophene Analog of Phencyclidine (some trade or
 other names:  1-[1-(2-thienyl) cyclohexyl] piperidine; 2-Thienyl
 Analog of Phencyclidine; TPCP, TCP);
 1-pyrrolidine (some trade or other name:  TCPy);
 1-(3-trifluoromethylphenyl)piperazine (trade or
 other name:  TFMPP); and
 3,4,5-trimethoxy amphetamine;
 (2)  Phenylacetone (some trade or other
 names:  Phenyl-2-propanone; P2P, Benzymethyl ketone, methyl benzyl
 ketone);
 (3)  unless specifically excepted or unless listed in
 another Penalty Group, a material, compound, mixture, or
 preparation that contains any quantity of the following substances
 having a potential for abuse associated with a depressant or
 stimulant effect on the central nervous system:
 Aminorex (some trade or other
 names:  aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5-
 phenyl-2-oxazolamine);
 Amphetamine, its salts, optical isomers, and
 salts of optical isomers;
 Cathinone (some trade or other names:  2-amino-1-
 phenyl-1-propanone, alpha-aminopropiophenone, 2-
 aminopropiophenone);
 Etaqualone and its salts;
 Etorphine Hydrochloride;
 Fenethylline and its salts;
 Lisdexamfetamine, including its salts, isomers,
 and salts of isomers;
 Mecloqualone and its salts;
 Methaqualone and its salts;
 Methcathinone (some trade or other names:  2-
 methylamino-propiophenone; alpha-(methylamino)propriophenone;
 2-(methylamino)-1-phenylpropan-1-one; alpha-N-
 methylaminopropriophenone; monomethylpropion; ephedrone, N-
 methylcathinone; methylcathinone; AL-464; AL-422; AL-463; and UR
 1431);
 N-Ethylamphetamine, its salts, optical isomers,
 and salts of optical isomers; and
 N,N-dimethylamphetamine (some trade or other
 names: N,N,alpha-trimethylbenzeneethanamine;
 N,N,alpha-trimethylphenethylamine), its salts, optical isomers,
 and salts of optical isomers;
 (4)  any compound structurally derived from
 2-aminopropanal by substitution at the 1-position with any
 monocyclic or fused-polycyclic ring system, including:
 (A)  compounds further modified by:
 (i)  substitution in the ring system to any
 extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or
 halide substituents), whether or not further substituted in the
 ring system by other substituents;
 (ii)  substitution at the 3-position with an
 alkyl substituent; or
 (iii)  substitution at the 2-amino nitrogen
 atom with alkyl, benzyl, dialkyl, or methoxybenzyl groups, or
 inclusion of the 2-amino nitrogen atom in a cyclic structure; and
 (B)  by example, compounds such as:
 4-Methylmethcathinone (Also known as
 Mephedrone);
 3,4-Dimethylmethcathinone (Also known as
 3,4-DMMC);
 3-Fluoromethcathinone (Also known as 3-FMC);
 4-Fluoromethcathinone (Also known as
 Flephedrone);
 3,4-Methylenedioxy-N-methylcathinone (Also
 known as Methylone);
 3,4-Methylenedioxypyrovalerone (Also known
 as MDPV);
 alpha-Pyrrolidinopentiophenone (Also known
 as alpha-PVP);
 Naphthylpyrovalerone  (Also known as
 Naphyrone);
 alpha-Methylamino-valerophenone (Also known
 as Pentedrone);
 beta-Keto-N-methylbenzodioxolylpropylamine
 (Also known as Butylone);
 beta-Keto-N-methylbenzodioxolylpentanamine
 (Also known as Pentylone);
 beta-Keto-Ethylbenzodioxolylbutanamine
 (Also known as Eutylone); and
 3,4-methylenedioxy-N-ethylcathinone (Also
 known as Ethylone);
 (5)  any compound structurally derived from tryptamine
 (3-(2-aminoethyl)indole) or a ring-hydroxy tryptamine:
 (A)  by modification in any of the following ways:
 (i)  by substitution at the amine nitrogen
 atom of the sidechain to any extent with alkyl or alkenyl groups or
 by inclusion of the amine nitrogen atom of the side chain (and no
 other atoms of the side chain) in a cyclic structure;
 (ii)  by substitution at the carbon atom
 adjacent to the nitrogen atom of the side chain (alpha-position)
 with an alkyl or alkenyl group;
 (iii)  by substitution in the 6-membered
 ring to any extent with alkyl, alkoxy, haloalkyl, thioaklyl,
 alkylenedioxy, or halide substituents; or
 (iv)  by substitution at the 2-position of
 the tryptamine ring system with an alkyl substituent; and
 (B)  including:
 (i)  ethers and esters of the controlled
 substances listed in this subdivision; and
 (ii)  by example, compounds such as:
 alpha-ethyltryptamine;
 alpha-methyltryptamine;
 Bufotenine (some trade and other names:
 3-(beta-Dimethylaminoethyl)-5-hydroxyindole;
 3-(2-dimethylaminoethyl)- 5- indolol; N, N-dimethylserotonin;
 5-hydroxy-N, N- dimethyltryptamine; mappine);
 Diethyltryptamine (some trade and
 other names: N, N-Diethyltryptamine, DET);
 Dimethyltryptamine (trade or other
 name: DMT);
 5-methoxy-N, N-diisopropyltryptamine
 (5-MeO-DiPT);
 O-Acetylpsilocin (Trade or other name:
 4-Aco-DMT);
 Psilocin; and
 Psilocybin;
 (6)  2,5-Dimethoxyphenethylamine and any compound
 structurally derived from 2,5-Dimethoxyphenethylamine by
 substitution at the 4-position of the phenyl ring to any extent
 (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide
 substituents), including, by example, compounds such as:
 4-Bromo-2,5-dimethoxyphenethylamine (trade or
 other name: 2C-B);
 4-Chloro-2,5-dimethoxyphenethylamine (trade or
 other name: 2C-C);
 2,5-Dimethoxy-4-methylphenethylamine (trade or
 other name: 2C-D);
 4-Ethyl-2,5-dimethoxyphenethylamine (trade or
 other name: 2C-E);
 4-Iodo-2,5-dimethoxyphenethylamine (trade or
 other name: 2C-I);
 2,5-Dimethoxy-4-nitrophenethylamine (trade or
 other name: 2C-N);
 2,5-Dimethoxy-4-(n)-propylphenethylamine (trade
 or other name: 2C-P);
 4-Ethylthio-2,5-dimethoxyphenethylamine (trade
 or other name: 2C-T-2);
 4-Isopropylthio-2,5-dimethoxyphenethylamine
 (trade or other name: 2C-T-4); and
 2,5-Dimethoxy-4-(n)-propylthiophenethylamine
 (trade or other name:  2C-T-7); and
 (7)  2,5-Dimethoxyamphetamine and any compound
 structurally derived from 2,5-Dimethoxyamphetamine by substitution
 at the 4-position of the phenyl ring to any extent (including alkyl,
 alkoxy, alkylenedioxy, haloalkyl, or halide substituents),
 including, by example, compounds such as:
 4-Ethylthio-2,5-dimethoxyamphetamine (trade or
 other name: Aleph-2);
 4-Isopropylthio-2,5-dimethoxyamphetamine (trade
 or other name: Aleph-4);
 4-Bromo-2,5-dimethoxyamphetamine (trade or other
 name: DOB);
 4-Chloro-2,5-dimethoxyamphetamine (trade or
 other name: DOC);
 2,5-Dimethoxy-4-ethylamphetamine (trade or other
 name: DOET);
 4-Iodo-2,5-dimethoxyamphetamine (trade or other
 name: DOI);
 2,5-Dimethoxy-4-methylamphetamine (trade or
 other name: DOM);
 2,5-Dimethoxy-4-nitroamphetamine (trade or other
 name: DON);
 4-Isopropyl-2,5-dimethoxyamphetamine (trade or
 other name: DOIP); and
 2,5-Dimethoxy-4-(n)-propylamphetamine (trade or
 other name: DOPR).
 SECTION 3.  Subchapter D, Chapter 481, Health and Safety
 Code, is amended by adding Section 481.1032 to read as follows:
 Sec. 481.1032.  PENALTY GROUP 2-B. (a) Penalty Group 2-B
 consists of any quantity of the following substances, their salts,
 isomers, and salts of isomers, unless specifically excepted, if the
 existence of these salts, isomers, and salts of isomers is possible
 within the specific chemical designation:
 Tetrahydrocannabinols, other than marihuana, and
 synthetic equivalents of the substances contained in the plant, or
 in the resinous extractives of Cannabis, or synthetic substances,
 derivatives, and their isomers with similar chemical structure and
 pharmacological activity such as:
 delta-1 cis or trans tetrahydrocannabinol, and
 their optical isomers;
 delta-6 cis or trans tetrahydrocannabinol, and
 their optical isomers;
 delta-3, 4 cis or trans tetrahydrocannabinol, and
 its optical isomers; or
 compounds of these structures, regardless of
 numerical designation of atomic positions, since nomenclature of
 these substances is not internationally standardized.
 (b)  For the purposes of this section, the term "isomer"
 includes an optical, position, or geometric isomer.
 SECTION 4.  Section 481.106, Health and Safety Code, is
 amended to read as follows:
 Sec. 481.106.  CLASSIFICATION OF CONTROLLED SUBSTANCE
 ANALOGUE. For the purposes of the prosecution of an offense under
 this subchapter involving the manufacture, delivery, or possession
 of a controlled substance, Penalty Groups 1, 1-A, 2, [and] 2-A, and
 2-B include a controlled substance analogue that:
 (1)  has a chemical structure substantially similar to
 the chemical structure of a controlled substance listed in the
 applicable penalty group; or
 (2)  is specifically designed to produce an effect
 substantially similar to, or greater than, a controlled substance
 listed in the applicable penalty group.
 SECTION 5.  The heading to Section 481.113, Health and
 Safety Code, is amended to read as follows:
 Sec. 481.113.  OFFENSE: MANUFACTURE OR DELIVERY OF SUBSTANCE
 IN PENALTY GROUP 2, [OR] 2-A, OR 2-B.
 SECTION 6.  Section 481.113(a), Health and Safety Code, is
 amended to read as follows:
 (a)  Except as authorized by this chapter, a person commits
 an offense if the person knowingly manufactures, delivers, or
 possesses with intent to deliver a controlled substance listed in
 Penalty Group 2, [or] 2-A, or 2-B.
 SECTION 7.  The heading to Section 481.1161, Health and
 Safety Code, is amended to read as follows:
 Sec. 481.1161.  OFFENSE: POSSESSION OF SUBSTANCE IN PENALTY
 GROUP 2-A OR 2-B.
 SECTION 8.  Section 481.1161(a), Health and Safety Code, is
 amended to read as follows:
 (a)  Except as authorized by this chapter, a person commits
 an offense if the person knowingly possesses a controlled substance
 listed in Penalty Group 2-A or 2-B, unless the person obtained the
 substance directly from or under a valid prescription or order of a
 practitioner acting in the course of professional practice.
 SECTION 9.  Section 481.122(a), Health and Safety Code, is
 amended to read as follows:
 (a)  A person commits an offense if the person knowingly
 delivers a controlled substance listed in Penalty Group 1, 1-A, 2,
 2-B, or 3 or knowingly delivers marihuana and the person delivers
 the controlled substance or marihuana to a person:
 (1)  who is a child;
 (2)  who is enrolled in a public or private primary or
 secondary school; or
 (3)  who the actor knows or believes intends to deliver
 the controlled substance or marihuana to a person described by
 Subdivision (1) or (2).
 SECTION 10.  Sections 551.003(11) and (12), Occupations
 Code, are amended to read as follows:
 (11)  "Controlled substance" means a substance,
 including a drug:
 (A)  listed in Schedule I, II, III, IV, or V, as
 established by the commissioner of public health under Chapter 481,
 Health and Safety Code, or in Penalty Group 1, 1-A, 2, 2-B, 3, or 4,
 Chapter 481; or
 (B)  included in Schedule I, II, III, IV, or V of
 the Comprehensive Drug Abuse Prevention and Control Act of 1970 (21
 U.S.C. Section 801 et seq.).
 (12)  "Dangerous drug" means a drug or device that:
 (A)  is not included in Penalty Group 1, 2, 2-B, 3,
 or 4, Chapter 481, Health and Safety Code, and is unsafe for
 self-medication; or
 (B)  bears or is required to bear the legend:
 (i)  "Caution: federal law prohibits
 dispensing without prescription" or "Rx only" or another legend
 that complies with federal law; or
 (ii)  "Caution: federal law restricts this
 drug to use by or on the order of a licensed veterinarian."
 SECTION 11.  The change in law made by this Act applies only
 to an offense committed on or after the effective date of this Act.
 An offense committed before the effective date of this Act is
 governed by the law in effect when the offense was committed, and
 the former law is continued in effect for that purpose. For purposes
 of this section, an offense was committed before the effective date
 of this Act if any element of the offense occurred before that date.
 SECTION 12.  This Act takes effect September 1, 2021.
 * * * * *